IONS insider files Form 144 to sell 124,850 shares ($7.63M)

Ionis Pharmaceuticals (IONS) reported a Form 144 notice for a proposed sale of 124,850 shares of common stock to be handled by Stifel Nicolaus & Company, Inc. on 09/03/2025 on Nasdaq with an aggregate market value of $7,634,553.00.

Rhea-AI Filing Summary

Ionis Pharmaceuticals (IONS) reported a Form 144 notice for a proposed sale of 124,850 shares of common stock to be handled by Stifel Nicolaus & Company, Inc. on 09/03/2025 on Nasdaq with an aggregate market value of $7,634,553.00. The shares were acquired on 01/04/2021 through an option exercise from the issuer and the planned consideration is cash. The filing also discloses a recent sale by Patrick O'Neil of 13,050 shares on 09/02/2025 for gross proceeds of $711,418.00. The filing includes the statutorily required declaration that the seller is not aware of undisclosed material adverse information.

Positive

• Disclosure compliance: The filer provided required Form 144 details, including acquisition method, broker, and sale amount.
• Transaction transparency: The filing states acquisition via option exercise and that proceeds are to be paid in cash, clarifying the nature of the sale.

Negative

• Insider sale size: Proposed sale valued at $7.63M could increase near-term share supply, though it is ~0.08% of outstanding shares.
• Recent insider selling: A prior sale of 13,050 shares on 09/02/2025 for $711,418 indicates ongoing insider liquidity activity in close succession.

Insights

Securities Analyst

TL;DR: Insider reports exercise-and-sale plan totaling $7.6M; small in relation to outstanding shares but relevant for near-term supply.

The Form 144 shows a proposed disposition of 124,850 shares valued at about $7.63 million, acquired in 2021 via option exercise and to be sold for cash through a broker on Nasdaq. Relative to the issuer's stated 159.39 million shares outstanding, the block represents roughly 0.08% of float, so the transaction is unlikely to materially affect capitalization but could create modest near-term selling pressure. The filing also documents a prior smaller sale of 13,050 shares for $711,418, indicating recent insider liquidity activity. This is routine insider disclosure rather than a corporate operational event.

Corporate Governance Expert

TL;DR: Form 144 is a compliance disclosure of insider sales; it raises governance transparency but not a material governance concern.

The notice documents the legal mechanics: shares were obtained by option exercise from the issuer and will be sold for cash via a registered broker. The signer affirms no undisclosed material adverse information, fulfilling Rule 144 representations. No evidence in the filing of a trading plan date, adverse disclosures, or related-party complexities. From a governance perspective, timely and complete filing supports regulatory compliance and investor transparency, without signaling a governance lapse.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What did the Form 144 filed for IONS disclose?

The Form 144 discloses a proposed sale of 124,850 common shares via Stifel Nicolaus on 09/03/2025 with aggregate market value $7,634,553.00.

How were the shares being sold by the filer acquired?

The shares were acquired on 01/04/2021 through an option exercise from the issuer.

Did the filing show any recent insider sales for IONS?

Yes. The filing reports Patrick O'Neil sold 13,050 shares on 09/02/2025 for gross proceeds of $711,418.00.

What exchange and broker are involved in the proposed sale?

The proposed sale is to occur on Nasdaq through Stifel Nicolaus & Company, Inc..

Does the filer state there is any undisclosed material information?

By signing the notice the person represents they do not know any material adverse information about the issuer that is not publicly disclosed.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 09/03/2025 - 05:15 PM Learn about SEC filing dates

Form 144 Filer Information	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 144 NOTICE OF PROPOSED SALE OF SECURITIES PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933
FORM 144

144: Filer Information

Filer CIK	0001564926
Filer CCC	XXXXXXXX
Is this a LIVE or TEST Filing?	LIVE TEST
Submission Contact Information
Name
Phone
E-Mail Address

144: Issuer Information

Name of Issuer	IONIS PHARMACEUTICALS INC
SEC File Number	000-19125
Address of Issuer	2855 GAZELLE COURT CARLSBAD CALIFORNIA 92010
Phone	7609319200
Name of Person for Whose Account the Securities are To Be Sold	O'NEIL PATRICK R.
See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.
Relationship to Issuer	Officer

144: Securities Information

Title of the Class of Securities To Be Sold	Name and Address of the Broker	Number of Shares or Other Units To Be Sold	Aggregate Market Value	Number of Shares or Other Units Outstanding	Approximate Date of Sale	Name the Securities Exchange
Common Stock	Stifel Nicolaus & Company Inc 501 N Broadway St. Louis MO 63102	124850	7634553.00	159391229	09/03/2025	Nasdaq

Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold

Title of the Class	Date you Acquired	Nature of Acquisition Transaction	Name of Person from Whom Acquired	Is this a Gift?	Date Donor Acquired	Amount of Securities Acquired	Date of Payment	Nature of Payment *
Common Stock	01/04/2021	Option Exercise	Issuer			124850	09/03/2025	Cash

* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.

Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

Name and Address of Seller	Title of Securities Sold	Date of Sale	Amount of Securities Sold	Gross Proceeds
Patrick O'Neil 2855 Gazette Ct Carlsbad CA 92010	Common Stock	09/02/2025	13050	711418.00

144: Remarks and Signature

Remarks
Date of Notice	09/03/2025
Date of Plan Adoption or Giving of Instruction, If Relying on Rule 10b5-1	05/01/2025
ATTENTION:
The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.
Signature	/s/ Luca Lotito, as a duly authorized representative of STIFEL, as attorney-in-fact for Patrick O'Neil
ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)